Navarixin

TargetMol
Product Code: TAR-T7130
Supplier: TargetMol
CodeSizePrice
TAR-T7130-1mg1mg£101.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T7130-5mg5mg£142.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T7130-1mL1 mL * 10 mM (in DMSO)£148.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T7130-10mg10mg£177.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T7130-25mg25mg£266.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T7130-50mg50mg£389.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T7130-100mg100mg£550.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T7130-500mg500mg£1,131.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT

Overview

Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃

Images

1 / 1

Further Information

Bioactivity:
Navarixin(SCH527123) is a novel, selective CXC chemokine receptor 2(CXCR2) antagonist that inhibits neutrophil activation and modulates neutrophil trafficking in animal models, characteristics that may be beneficial in the treatment of conditions with unbalanced pulmonary neutrophilia.
CAS:
473727-83-2
Formula:
C21H23N3O5
Molecular Weight:
397.431
Pathway:
Autophagy; GPCR/G Protein; Immunology/Inflammation
Purity:
0.9863
SMILES:
CC[C@@H](Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1ccc(C)o1
Target:
CXCR

References

Gonsiorek W , Fan X , Hesk D , et al. Pharmacological Characterization of Sch527123, a Potent Allosteric CXCR1/CXCR2 Antagonist[J]. Journal of Pharmacology and Experimental Therapeutics, 2007, 322(2):477-485. Holz O, Khalilieh S, Ludwig-Sengpiel A,et al.SCH527123, a novel CXCR2 antagonist, inhibits ozone-induced neutrophilia in healthy subjects[J].Eur Respir J. 2010 Mar;35(3):564-70. Luo Q, Dong Z, Xie W, et al.Apatinib remodels the immunosuppressive tumor ecosystem of gastric cancer enhancing anti-PD-1 immunotherapy.Cell Reports.2023, 42(5).